UK health technology assessor the National Institute for Health
and Care Excellence (NICE) has issued a Final Appraisal Document
recommending Rinvoq (upadacitinib), from US drugmaker AbbVie
(NYSE: ABBV), as a treatment of moderate to severe atopic
dermatitis (AD) for adults and young people aged 12 and over, if
the disease has not responded to at least 1 systemic
immunosuppressant, or these are not
suitable. Upadacitinib has been recommended…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.